Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Last updated refers to the date when our listing for each treatment was last updated.
ID is our internal ID - starting with VT.
Min Karnofsky is a general guide to how well you have to function to use this treatment
For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.

Back to New Treatments List



		Treatment Name:		Phase I/II study of sorafenib with radiation and temozolomide in newly diagnosed glioblastoma or gliosarcoma

		Keywords:		sorafenib, radiation, temozolomide

		Phase:		Phase 1/2

		Treatment ID#s:		VT1898 2008-0059

		Age Group:		Adults Only

		Min Karnofsky Score:		60: Requires occasional assistance but is able to care for most of own needs

		Conditions:		Newly Diagnosed: Y Recurrent: N Prior Surgery is Allowed Prior Radiation is Not Allowed Prior Chemotherapy is Sometimes Allowed newly diagnosed glioblastoma or gliosarcoma

		Last Updated:		04/03/2009

		Tumor Types:		Glioblastoma Multiforme Gliosarcoma


		Comments:		Sorafenib is a multi-functional small molecule inhibitor that targets both the Raf/MAP kinase pathway and VEGF receptors. Study includes tumor tissue analyses for tumor profiling.

		Treatment Type:		Chemotherapy Radiation Immunological, Biological or Targeted Therapy.

		Contact:		MD Anderson Cancer Center Jan Esenwein Program Coordinator, Brain Tumor Program Contact: Jan Esenwein or Marie Woodward 1515 Holcombe Blvd Houston, TX 77030- Phone:(713)745-2264 Fax: (713)794-4999 Click here to send an email Website: www.mdanderson.org/diseases/braincancer/

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By